BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces Fiscal Year 2013 Financial Results


12/27/2013 6:30:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MISSION VIEJO, CA--(Marketwired - December 23, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three months and twelve months ended September 30, 2013.

Key 2013 Operational Accomplishments

  • Exercise of $6.0 million in additional options under BARDA contract
  • Filing of application for new patents for AEOL 10150 covering synthesis, formulation and pharmaceutical composition potentially extending protection through 2034.
  • Completion of additional animal studies in Lung-ARS demonstrating significant survival advantage.
  • Award of $4.3 million NIH grant to develop AEOL 10150 as treatment for nerve gas exposure
  • Initiation of large non-human primate study with AEOL 10150 in Lung-ARS
  • Release of data from multiple animal studies demonstrating efficacy for AEOL 10150 in mustard gas exposure
  • Addition of new Directors to Board with expertise in government affairs and radiation oncology

"Our team made significant progress during fiscal 2013 in advancing AEOL 10150 as a medical countermeasure for radiation and chemical exposure. The additional efficacy data generated in radiation and mustard gas models confirms the effectiveness of AEOL 10150 as a medical countermeasure. Work in the manufacturing segment of our BARDA program has resulted in the filing of new patents, a greater than 80 percent reduction in the cost of goods, and scale up of our manufacturing process from 1 kilogram batches to 4.5 kilogram batches," stated John L. McManus, President & Chief Executive Officer of Aeolus Pharmaceuticals, Inc. "2014 will be an exciting year as we expect to report results from at least 8 animal efficacy studies for radiation, and several studies in our sulfur mustard, nerve agent and Parkinson's disease programs, and expect to file several IND's and a pre-emergency use authorization. We remain grateful for the funding and the technical expertise that our partners at BARDA, NIH-NIAID and NIH CounterACT continue to provide, and the valuable contributions from our research collaborators at the University of Maryland, National Jewish Health, University of Colorado, Indiana University, Johnson Matthey Pharma Services and Epistem."

Financial Results

The Company reported a net loss of $3,208,000 or ($0.03) per share (including a non-cash adjustment for increases in valuation of warrants of approximately $510,000) for the fiscal year ended September 30, 2013, versus net income of $1,698,000 or $0.01 per share (including a non-cash gain for decreases in valuation of warrants of $4,069,000) for the fiscal year ended September 30, 2012.

Revenue for the fiscal year ended September 30, 2013 was approximately $3,928,000, compared to $7,293,000 for the fiscal year ended September 30, 2012. The revenue is from the contract with the Biomedical Advanced Research and Development Authority ("BARDA") announced on February 11, 2011. Lower revenue in fiscal year 2013 reflects the timing of the initiation of program items under the BARDA contract.

Research and development expenses decreased by $3,108,000, or 48%, to approximately $3,360,000 for the fiscal year ended September 30, 2013 from approximately $6,468,000 for the fiscal year ended September 30, 2012. R&D expenses were lower during the fiscal year ended September 30, 2013 versus September 30, 2012 due to the timing of work related to the BARDA contract.

G&A expenses increased approximately $70,000, or 2%, to approximately $3,266,000 for the fiscal year ended September 30, 2013 from about $3,196,000 for the fiscal year ended September 30, 2012. Consulting stock expense increased by about $287,000 as a result of increased awards for the period. The increase in consulting stock expense was partially offset by a decrease in salaries and benefits of about $172,000.

For the fourth quarter of FY 2013, total revenues were $0.9 million as compared to $1.4 million in the fourth quarter of FY 2012. Net loss for the fourth quarter in FY 2013 was $0.7 million, which includes no adjustments related to warrant liability, as compared to $7.1 million, which includes a loss of approximately $6.6 million related to decreases in the fair value of the warrants, in the fourth quarter of FY 2012.

Aeolus has filed today with the SEC its Annual Report on Form 10-K for the fiscal year ended September 30, 2013. Aeolus urges its investors to read this quarterly filing as well as its amended Annual Report on Form 10-K/A, also filed with the SEC, for further details concerning the Company. The Quarterly Report on Form 10-Q and the amended Annual Report on Form 10-K/A are also available on the Company's website, at http://www.aeoluspharma.com.

About AEOL 10150
AEOL 10150 is a broad-spectrum catalytic antioxidant specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure. AEOL 10150 may have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation in the treatment of oncology.

AEOL 10150 has performed well in preclinical and non-clinical studies, demonstrating statistically significant survival efficacy in an acute radiation-induced lung injury model, and was well-tolerated in two human clinical trials. The Company believes it could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation, whether from cancer therapy or a nuclear event.

About Aeolus Pharmaceuticals
Aeolus Pharmaceuticals is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation and other inducers of reactive oxygen species. Its first compound, AEOL 10150, is being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118.4 million, to efficiently develop the compound for use in oncology. For more information, please visit Aeolus's corporate website at www.aeoluspharma.com.

Forward-Looking Statements

The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs, the Company's potential initiation of large efficacy studies in mice and NHPs, as well as a phase 1 study in healthy normal volunteers, the BARDA Contract, and the expected use of proceeds from the financing. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and competition from other biopharmaceutical companies, and whether BARDA exercises one or more additional options under the BARDA Contract. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' Annual Report on Form 10-K for the year ended September 30, 2012. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

                                                                            
                        AEOLUS PHARMACEUTICALS, INC.                        
                   CONDENSED CONSOLIDATED BALANCE SHEETS                    
                                 (Unaudited)                                
               (In thousands, except share and per share data)              
                                                                            
                                                         September 30,      
                                                   ------------------------ 
                                                       2013         2012    
                                                   -----------  ----------- 
                      ASSETS                                                
Current assets:                                                             
Cash and cash equivalents                          $       869  $       281 
Accounts receivable                                        370          781 
Deferred subcontractor cost                                656          101 
Prepaids and other current assets                           39           61 
Total current assets                                     1,935        1,224 
                                                                            
Investment in CPEC LLC                                      32           32 
                                                   -----------  ----------- 
Total assets                                       $     1,966  $     1,256 
                                                   ===========  =========== 
                                                                            
  LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                            
Current liabilities:                                                        
Accounts payable and accrued expenses              $       579  $     2,167 
Deferred revenue                                           682          105 
                                                   -----------  ----------- 
Total current liabilities                                1,261        2,272 
                                                                            
Warrant liability                                           --       19,319 
                                                   -----------  ----------- 
Total liabilities                                        1,261       21,591 
                                                                            
Commitments and Contingencies (Notes E and I)                               
                                                                            
Stockholders' equity (deficit):                                             
Preferred stock, $.01 par value per share,                                  
 10,000,000 shares authorized:                                              
Series A nonredeemable convertible preferred                                
 stock, 1,250,000 shares authorized as of                                   
 September 30, 2013 and 2012, respectively; no                              
 shares issued and outstanding as of September 30,                          
 2013 and 2012, respectively                                --           -- 
Series B nonredeemable convertible preferred                                
 stock, 1,600,000 and 600,000 shares authorized as                          
 of September 30, 2013 and 2012, respectively;                              
 526,080 and 526,080 shares issued and outstanding                          
 as of September 30, 2013 and 2012, respectively             5            5 
Common stock, $.01 par value per share,                                     
 200,000,000 shares authorized; 134,550,068 and                             
 62,731,963 shares issued and outstanding at                                
 September 30, 2013 and 2012, respectively               1,346          627 
Additional paid-in capital                             183,276      159,747 
Accumulated deficit                                   (183,922)    (180,714)
                                                   -----------  ----------- 
Total stockholders' equity (deficit)                       705      (20,335)
                                                   -----------  ----------- 
Total liabilities and stockholders' equity                                  
 (deficit)                                         $     1,966  $     1,256 
                                                   ===========  =========== 
                                                                            

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

                                                                            
                        AEOLUS PHARMACEUTICALS, INC.                        
              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS               
                                 (Unaudited)                                
                    (In thousands, except per share data)                   
                                                                            
                                           Fiscal Year Ended September 30,  
                                         ---------------------------------- 
                                               2013              2012       
                                         ----------------  ---------------- 
Revenue:                                                                    
Contract revenue                         $          3,928  $          7,293 
                                                                            
Costs and expenses:                                                         
Research and development                            3,360             6,468 
General and administrative                          3,266             3,196 
                                         ----------------  ---------------- 
Total costs and expenses                            6,626             9,664 
                                         ----------------  ---------------- 
                                                                            
Loss from operations                               (2,698)           (2,371)
Warrant liability gain (charges)                     (510)            4,069 
                                         ----------------  ---------------- 
Net income (loss)                        $         (3,208) $          1,698 
                                         ================  ================ 
                                                                            
Net income (loss) attributable to common                                    
 stockholders - basic                    $         (3,208) $            856 
Net income (loss) attributable to common                                    
 stockholders - diluted                  $         (3,208) $         (2,161)
                                                                            
Basic net income (loss) per common share $          (0.03) $           0.01 
                                         ================  ================ 
Diluted net income (loss) per common                                        
 share                                   $          (0.03) $          (0.03)
                                         ================  ================ 
                                                                            
Weighted average common shares                                              
 outstanding:                                                               
Basic                                             106,554            61,593 
                                         ================  ================ 
Diluted                                           106,554            71,041 
                                         ================  ================ 
                                                                            

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

                                                                            
                        AEOLUS PHARMACEUTICALS, INC.                        
              CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS               
                                 (Unaudited)                                
                                (In thousands)                              
                                                        Fiscal Year Ended   
                                                          September 30,     
                                                      --------------------- 
                                                         2013        2012   
                                                      ---------   --------- 
Cash flows from operating activities:                                       
Net income (loss)                                     $  (3,208)  $   1,698 
Adjustments to reconcile net income (loss) to net                           
 cash used in operating activities:                                         
  Depreciation                                                6           7 
  Noncash compensation                                      861         568 
  Noncash interest and financing costs                       --          17 
  Change in fair value of warrants                          510      (4,086)
Change in assets and liabilities:                                           
  Accounts receivable                                       411         896 
  Deferred subcontractor cost                              (555)       (101)
  Prepaid expenses and other assets                          16          (6)
  Accounts payable and accrued expenses                  (1,588)         23 
  Deferred revenue                                          577         105 
                                                      ---------   --------- 
Net cash used in operating activities                    (2,970)       (879)
                                                                            
Cash flows from investing activities:                                       
  Purchase of equipment                                      --          -- 
                                                      ---------   --------- 
Net cash used in investing activities                        --          -- 
                                                      ---------   --------- 
                                                                            
Cash flows from financing activities:                                       
  Proceeds from issuance of common stock and                                
   warrants                                               3,616         660 
  Costs related to the issuance of common stock and                         
   warrants                                                 (58)        (18)
                                                      ---------   --------- 
Net cash provided by financing activities                 3,558         642 
                                                                            
Net increase (decrease) in cash and cash equivalents        588        (237)
                                                                            
Cash and cash equivalents at beginning of year              281         518 
                                                      ---------   --------- 
Cash and cash equivalents at end of year              $     869   $     281 
                                                      =========   ========= 
                                                                            

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


Contact:

John McManus
President and Chief Executive Officer
Aeolus Pharmaceuticals, Inc.
1-(949) 481-9825

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Hey, check out all the research scientist jobs. Post your resume today!


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES